Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | AGL | Common Stock | Purchase | +5.43K | +9.29% | 63.9K | Mar 14, 2024 | Direct | F1, F2, F3 | ||
transaction | AGL | Common Stock | Tax liability | -$9.85K | -1.88K | -2.94% | $5.23 | 62.1K | Mar 14, 2024 | Direct | F4, F5 |
Id | Content |
---|---|
F1 | This award was granted on April 14, 2021 and all remaining performance-based restricted stock units (PSUs) subject to the award vested on March 14, 2024. |
F2 | The number of PSUs that vested was determined based on agilon health's predetermined Revenue and Adjusted EBITDA goals over a three-year period from January 1, 2021 through December 31, 2023. Total attainment achieved was 100%. |
F3 | Each PSU represents the right to receive, at settlement, one share of common stock. This transaction represents the settlement of PSUs in shares of common stock on their scheduled vesting date. |
F4 | Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the PSUs and does not represent a sale. |
F5 | Includes restricted stock units. |